Xenetic Biosciences (XBIO) EBT Margin (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly EBT Margin came in at 5001.27% in Q1 2026, up 212936.0% YoY from N/an in Q1 2025, and down 6051.34% on a QoQ basis from 81.3% in Q4 2025.
Xenetic Biosciences (XBIO) EBT Margin (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 13 years of EBT Margin data on file, last reported at 5001.27% in Q1 2026.
- Quarterly EBT Margin rose 212936.0% year-over-year to 5001.27% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3935.6% (up 95222.0% YoY) and the FY2025 annual result came in at 1432.42%, up 38074.0% from the prior year.
- EBT Margin fell to 5001.27% in Q1 2026, from 81.3% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 81.3% in Q4 2025 to a low of 8591.34% in Q1 2022.
- A 5-year average of 5248.05% and a median of 6538.84% in 2023 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 776142 bps in 2022, down 773581 bps in 2022.
- Tracing XBIO's EBT Margin over 5 years: stood at 326.58% in 2022, then surged by 43 bps to 186.87% in 2023, then increased by 9 bps to 169.41% in 2024, then jumped by 52 bps to 81.3% in 2025, then plunged by 6051 bps to 5001.27% in 2026.
- The last three EBT Margin figures came in at 5001.27% (Q1 2026), 81.3% (Q4 2025), and 4113.58% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - | -140.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6,226.09% |
| Mar 31, 2026 | -5,001.27% |
| Dec 31, 2025 | -81.30% |
| Sep 30, 2025 | -4,113.58% |
| Jun 30, 2025 | -7,174.88% |
| Mar 31, 2025 | -7,130.63% |
| Dec 31, 2024 | -169.41% |
| Sep 30, 2024 | -6,691.08% |
| Jun 30, 2024 | -5,745.76% |
| Mar 31, 2024 | -8,098.48% |
| Dec 31, 2023 | -186.87% |
| Sep 30, 2023 | -6,601.51% |
| Jun 30, 2023 | -6,174.79% |
| Mar 31, 2023 | -6,538.84% |
| Dec 31, 2022 | -326.58% |
| Sep 30, 2022 | -8,122.58% |
| Jun 30, 2022 | -8,468.02% |
| Mar 31, 2022 | -8,591.34% |
| Dec 31, 2021 | -566.23% |
| Sep 30, 2021 | -386.77% |